These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 17971409

  • 21. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD, Palumbo FB, Saba M.
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Jun; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin.
    Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E.
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):115-21. PubMed ID: 16342302
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 33. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
    Linton A, Bacon T, Peterson M.
    J Manag Care Pharm; 2009 May; 15(1):42-54. PubMed ID: 19125549
    [Abstract] [Full Text] [Related]

  • 34. The effect of switching on compliance and persistence: the case of statin treatment.
    Thiebaud P, Patel BV, Nichol MB, Berenbeim DM.
    Am J Manag Care; 2005 Nov; 11(11):670-4. PubMed ID: 16268750
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Plan-sponsor savings and member experience with point-of-service prescription step therapy.
    Motheral BR, Henderson R, Cox ER.
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):457-64. PubMed ID: 15298367
    [Abstract] [Full Text] [Related]

  • 38. Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
    Paulós CP, Nygren CE, Celedón C, Cárcamo CA.
    Ann Pharmacother; 2005 May; 39(5):939-43. PubMed ID: 15827075
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.